SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

The Trade Desk, Inc. engages in the provision of a self-service and cloud-based ad-buying platform. It operates through the United States and International geographical segments. The firm offers omnichannel advertising, audience targeting, solutions for identity, application programming interface (API), custom, and programmatic, measurement and optimization. The company was founded by Jeffrey Terry Green and David Pickles in November 2009 and is headquartered in Ventura, CA.

Trade Desk Inc - Ordinary Shares - Class A

Trade Desk Inc

The Trade Desk is trending following a massive insider share purchase by CEO Jeff Green, signaling strong executive confidence, alongside widespread rumors of an OpenAI partnership for ad sales. The community is buzzing with speculation about a potential short squeeze for the recently oversold stock, viewing these developments as a significant catalyst amidst competitive pressures in the ad-tech sector.

Alibaba Group Holding Ltd. engages in providing technology infrastructure and marketing reach. It operates through the following business segments: China Commerce, International Commerce, Local Consumer Services, Cainiao, Cloud, Digital Media and Entertainment, and Innovation Initiatives and Others segments. The Core Commerce segment consists of platforms operating in retail and wholesale. The China Commerce segment includes China commerce retail and wholesale businesses. The International Commerce segment focuses on international commerce retail and wholesale businesses. The Local Consumer Services segment is involved in To-Home businesses, which include Ele.me, local services and delivery platform, and Taoxianda, and To-Destination segment businesses which include Amap, the provider of mobile digital map, navigation and real-time traffic information, and restaurant and local services guide platform. The Cainiao segment has Cainiao Network and offers domestic and international one-stop-shop logistics services and supply chain management solution. The Cloud segment includes Alibaba Cloud and DingTalk. The company was founded by Chung Tsai and Yun Ma on June 28, 1999 and is headquartered in Hangzhou, China.

Alibaba Group Holding Ltd - ADR

Alibaba Group Holding Ltd

Alibaba is trending due to widespread investor confusion regarding its unannounced earnings report and lingering concerns from a recent, though withdrawn, US Pentagon listing. While many express extreme frustration over its performance and geopolitical pressures, a strong counter-narrative highlights the stock as deeply oversold and poised for a rebound fueled by its Qwen AI developments.

JD.com, Inc. is a technology-driven E-commerce company, which engages in the sale of electronics products and general merchandise products, including audio, video products, and books. It operates in the following segments: JD Retail, JD Logistics, and New Businesses. The JD Retail segment offers online retail, online marketplace, and marketing services. The JD Logistics segment includes internal and external logistics businesses. The New Businesses segment is composed of JD Property, Jingxi, overseas businesses and technology initiatives. The company was founded on June 18, 1998, by Qiang Dong Liu and is headquartered in Beijing, China.

JD.com Inc - ADR

JD.com is trending as its highly anticipated earnings report approaches, fueling intense debate and frustration among investors over continuous price declines to new 52-week lows, even as discussions highlight its strong fundamentals and competitive advantages in logistics within the fierce Chinese e-commerce landscape.

Snap, Inc. is a technology company, which engages in the provision of a visual messaging application that was created to help people communicate through short videos and images. The company was founded by Frank Reginald Brown IV, Evan Thomas Spiegel, and Robert C. Murphy in 2010 and is headquartered in Santa Monica, CA.

Snap Inc - Ordinary Shares - Class A

Snap Inc

Snap Inc. is trending as the community highlights its recent achievement of profitability and the significant growth of its direct revenue business, with Snapchat+ subscriptions now exceeding 25 million and reaching a substantial annualized run rate. Despite these strong financial and user engagement milestones, investors are expressing frustration over the stock's current valuation, fueling discussions of a potential rebound or strategic acquisition given its innovation in AI and AR.

IREN Ltd. is a vertically integrated data center business powering the future of Bitcoin, AI and beyond with renewable energy. It is strategically located in renewable-rich, fiber-connected regions across the US and Canada. IREN’s large-scale, grid-connected facilities are purpose-built for the next generation of power-dense computing applications. The company was founded by Daniel Roberts and William Roberts on November 6, 2018, and is headquartered in Sydney, Australia.

IREN Ltd.

IREN Limited

IREN is trending following its announcement of substantial orders for Nvidia GPUs to significantly expand its AI cloud fleet and ambitious revenue targets. This major expansion is largely to be funded by a new $6 billion At-The-Market offering, leading to intense community discussion about potential shareholder dilution versus the strategic need for capital to become a dominant AI infrastructure provider.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricor Therapeutics is trending as the community eagerly discusses its recently submitted BLA for Deramiocel, fueled by strong HOPE-3 trial data for Duchenne muscular dystrophy and intensifying political pressure on the FDA for accelerated rare disease approvals. Investors are closely watching for an imminent PDUFA date, anticipating a significant re-rating of the stock.

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla is trending due to a bullish analyst upgrade emphasizing its leadership in autonomy and future robotaxi services, amplified by Elon Musk's claims about the company's progress in artificial general intelligence. This sparks fervent community debate, with bulls envisioning a new growth era from these innovations, while skeptics highlight declining EV sales and FSD's supervised status, often accusing the stock of being 'manipulated' amidst ambitious projections.

Uniting the six native Japanese dog breeds. Kendu is the keeper of peace, the preserver of life, and the protector of unity. Join the pack!!

Kendu

KENDU CRYPTO is trending as its highly engaged community actively promotes its unique 'permissionless brand' model, emphasizing continuous real-world product development and events, positioning it as a conviction play to accumulate amidst market dips.

Meta Platforms, Inc. engages in the development of social media applications. It builds technology that helps people connect and share, find communities, and grow businesses. It operates through the Family of Apps (FoA) and Reality Labs (RL) segments. The FoA segment consists of Facebook, Instagram, Messenger, WhatsApp, and other services. The RL segment includes augmented, mixed and virtual reality related consumer hardware, software, and content. The company was founded by Mark Elliot Zuckerberg, Dustin Moskovitz, Chris R. Hughes, Andrew McCollum, and Eduardo P. Saverin on February 4, 2004, and is headquartered in Menlo Park, CA.

Meta Platforms Inc - Ordinary Shares - Class A

Meta Platforms Inc

Meta Platforms is a hot topic following its multi-year deal with AMD for AI chips, a partnership that includes performance-based warrants and underscores Meta's extensive commitment to building out its AI infrastructure. The community is keenly focused on the company's strategy to diversify its chip supply and scale AI capabilities to enhance platform engagement and drive future growth.

Caterpillar, Inc. engages in the business of manufacturing construction and mining equipment, off-highway diesel and natural gas engines, industrial gas turbines, and diesel-electric locomotives. It operates through the following segments: Construction Industries, Resource Industries, Energy and Transportation, Financial Products, and All Other. The Construction Industries segment is involved in supporting customers using machinery in infrastructure and building construction applications. The Resource Industries segment offers machinery in mining, heavy construction, quarry, and aggregates. The Energy and Transportation segment focuses on reciprocating engines, turbines, diesel-electric locomotives, and related services across industries serving oil and gas, power generation, industrial, and transportation applications including marine- and rail-related businesses. The Financial Products segment provides financing alternatives to customers and dealers for Caterpillar products and services, as well as financing for power generation facilities. The All Other segment includes activities such as the business strategy, product management and development, manufacturing, and sourcing of wear and maintenance components products, parts distribution, integrated logistics solutions, distribution services responsible for dealer development, and administration. The company was founded on April 15, 1925 and is headquartered in Irving, TX.

Caterpillar Inc.

Caterpillar is at the forefront of market discussion due to booming demand for its power generation equipment, specifically gas turbines, driven by the rapid expansion of AI data centers, which has prompted recent analyst upgrades and a partnership with Nvidia. While this new AI-adjacent narrative fuels strong bullish momentum and sector rotation, a significant portion of the community views the industrial stock as profoundly overvalued and ripe for a correction, citing high valuation metrics and insider selling.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

BioLineRx Reports Third Quarter 2025 Financial Results and Provides Corporate Update

BioLineRx Reports Third Quarter 2025 Financial Results and Provides Corporate Update BioLineRx Reports Third Quarter 2025 Financial Results and Provides Corporate Update PR Newswire TEL AVIV, Israel...

BioLineRx to Report Third Quarter 2025 Results on November 24, 2025

BioLineRx to Report Third Quarter 2025 Results on November 24, 2025 BioLineRx to Report Third Quarter 2025 Results on November 24, 2025 PR Newswire TEL AVIV, Israel, Nov. 18, 2025 Management to Hold...

BioLineRx Announces Receipt of USPTO Notice of Allowance for Key Patent Covering GLIX1 for Treating a Broad Range of Cancer Types

BioLineRx Announces Receipt of USPTO Notice of Allowance for Key Patent Covering GLIX1 for Treating a Broad Range of Cancer Types BioLineRx Announces Receipt of USPTO Notice of Allowance for Key...

Shares of BioLineRx (BLRX) skyrocketed 32% on Friday after the biopharmaceutical company <a target="_blank" rel="noopener noreferrer nofollow" href="https://ir.biolinerx.com/news-releases/news-release-details/biolinerx-announces-new-pilot-phase-data-phase-2-combination">announced</a> positive data from the single-arm pilot phase of its Phase 2 trial evaluating its drug in the treatment of pancreatic cancer.The study is evaluating the company’s Motixafortide, Cemiplimab, and standard-of-care chemotherapies Gemcitabine and Nab-paclitaxel, versus Gemcitabine and Nab-paclitaxel alone, in first-line pancreatic cancer (PDAC).The company said that updated results from the pilot phase indicate that four of eleven patients remained disease progression-free after more than one year. Progression-free means that the patient's disease did not get worse or spread.CEO Philip Serlin said that the data emerging from the pilot phase of the study are “extremely encouraging,” while also noting that pancreatic cancer is the “most challenging” tumor to treat.The company also stated that it now plans to enroll 108 patients in the Phase 2 trial, which will be a randomized study, based on the results of the pilot phase. The company had previously planned to enroll only 30 patients in the study.The trial is planned to be fully enrolled in 2027. While the trial's primary endpoint is progression-free survival (PFS), secondary objectives include safety, response rate, disease control rate, duration of clinical benefit, and overall survival.Following the news, Jones Research upgraded BioLineRx to ‘Buy’ from ‘Hold’ with a $12 price target. With these results, BioLineRx will have additional opportunities to either partner the asset or fund a pivotal trial, assuming favorable Phase II results, the analyst said.On Stocktwits, retail sentiment around BLRX jumped from ‘bullish’ to ‘extremely bullish’ territory over the past 24 hours while message volume stayed at ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:626/68;" src="https://news.stocktwits-cdn.com/Screenshot_2025_05_30_at_12_47_05_PM_png_ca2195fcbe.webp" alt="BLRX's Sentiment Meter and Message Volume as of 12:45 p.m. ET on May 30, 2025 | Source: Stocktwits" width="626" height="68"><figcaption>BLRX's Sentiment Meter and Message Volume as of 12:45 p.m. ET on May 30, 2025 | Source: Stocktwits</figcaption></figure> <a href="https://stocktwits.com/symbol/BLRX">BLRX</a> is down by about 50% this year and by about 84% over the past 12 months.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/gilead-eyeing-hiv-drug-rollout-in-low-income-countries-report/ch0ubVvRbuE">Gilead Eyes HIV Drug Rollout In Low-Income Countries Despite Funding Uncertainty, Says Report: Retail Holds Onto Bearish Stance</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

BioLineRx Stock Jumps On Positive Data from Pilot Phase Of Pancreatic Cancer Drug Trial: Retail Cheers The ‘Buy’ Rating

The company said that updated results from the pilot phase indicate that four of eleven patients remained disease progression-free after more than one year.

Equity

Nasdaq-listed shares of BioLineRx (BLRX) traded 4% higher on Tuesday afternoon after the company reported an over 600% year-on-year jump in its first-quarter net income.The Israel-based biopharmaceutical company <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.prnewswire.com/news-releases/biolinerx-reports-first-quarter-2025-financial-results-and-provides-corporate-update-302465635.html">reported</a> revenues for the three months ended March 31, 2025, of $0.3 million, compared to revenues of $6.9 million in the year-ago period, and below an analyst estimate of $1 million, as per Koyfin data.BioLineRx out-licensed its FDA-approved Aphexda, used in treating a type of cancer called multiple myeloma, to Ayrmid last November and shut its U.S. commercial operations by the year-end.Aphexda, however, generated sales of $1.4 million in the first quarter, providing the company with $0.3 million in royalties.The fall in revenue in the first quarter reflects the company’s change in operation after out-licensing Aphexda, it said.Net income for the quarter ended March 31, 2025, was $5.1 million, compared to $0.7 million for the quarter ended March 31, 2024, and above an estimated net loss of $3 million. The net non-operating income stood at $7.6 million, compared to net non-operating income of $4.5 million in the three months ended March 31, 2024.The company ended the quarter with cash, cash equivalents, and short-term bank deposits of $26.4 million, which it expects to be sufficient through the second half of 2026.CEO Philip Serlin said that the company has been actively evaluating new assets in the areas of oncology and rare diseases, where it can leverage its expertise after out-licensing Aphexda."I remain optimistic that we will announce a meaningful transaction this year," he said.On Stocktwits, retail sentiment around BioLineRx rose within the ‘extremely bullish’ territory over the past 24 hours while message volume remained at ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:627/65;" src="https://news.stocktwits-cdn.com/Screenshot_2025_05_27_at_1_49_08_PM_png_c44b3d7c0e.webp" alt="BLRX's Sentiment Meter and Message Volume as of 1:50 p.m. ET on May 27, 2025 | Source: Stocktwits " width="627" height="65"><figcaption>BLRX's Sentiment Meter and Message Volume as of 1:50 p.m. ET on May 27, 2025 | Source: Stocktwits&nbsp;</figcaption></figure><a href="https://stocktwits.com/symbol/BLRX">BLRX stock</a> is down by about 63% this year and nearly 87% over the past 12 months.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/byd-sued-by-brazil-prosecutors-for-alleged-human-trafficking/ch0V1GJRbra">BYD Sued By Brazil Prosecutors For Alleged Human Trafficking: Retail’s In Wait-And-Watch Mode</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Global stock market chart and trading board - stock photo

BioLineRx Q1 Earnings Rise Despite Fall In Revenue: Retail Stays Super Confident

CEO Philip Serlin said that the company has been actively evaluating new assets in the areas of oncology and rare diseases, where it can leverage its expertise after out-licensing Aphexda. 

BioLineRx Ltd. is a clinical stage biopharmaceutical company, which engages in the research and development of treatments that focus on cancer. Its product pipeline includes Motaxafortide (BL-8040), which is used for stem-cell mobilization, solid tumors, and acute myeloid lukemia; and AGI-134, which is an immunotherapy treatment used for multiple solid tumors. The company was founded in 2003 and is headquartered in Modi'in, Israel.

BLRX
BioLineRx, Ltd.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest BLRX News

BLRXBioLineRx, Ltd.